CJC-1295 explained: with and without DAC
What the Drug Affinity Complex changes, and why it matters for study design.
Research context
CJC-1295 is a GHRH analogue. The DAC modification allows binding to albumin, which extends its half-life in research models.
Reading the evidence
Much of the available literature comes from cell and animal models. Findings should be read with attention to study design, sample size and whether results have been independently replicated.
A note on use
Silsila products are presented for laboratory research only. Nothing in this journal is medical advice, and no product is intended for human or veterinary use.
Sources & evidence
Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295 in healthy adults
CJC-1295 was studied alone in healthy adults. Hormone responses do not establish a therapeutic benefit or the effectiveness of a combination.
Read original sourceHuman growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor
Albumin binding was investigated as a way to extend activity; evidence for this compound should not be generalized to products labelled without DAC.
Read original sourceA study indexed in PubMed or hosted on PMC is not NIH or FDA approval. Findings for approved medicines do not establish the safety or effectiveness of Silsila products.